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ABSTRACT  Cancers promote immunological stresses that induce alter-
ations of the myelopoietic output, defined as emergency myelopoiesis, 
which lead to the generation of different myeloid populations en-
dowed with tumor-promoting activities. New evidence indicates that 
acquisition of this tumor-promoting phenotype by myeloid cells is the 
result of a multistep process, encompassing initial events originating 
into the bone marrow and later steps operating in the tumor microen-
vironment. The careful characterization of these sequential mecha-
nisms is likely to offer new potential therapeutic opportunities. Here, 
we describe relevant mechanisms of myeloid cells reprogramming that 
instate immune dysfunctions and limit effective responses to anti-
cancer therapy and discuss the influence that metabolic events, as well 
as chemotherapy, elicit on such events. 
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The bone marrow (BM) is a primary lymphoid organ that 
hosts hematopoietic progenitors and presides over hema-
topoiesis, which is defined as the production of all types of 
blood cells. Under steady-state conditions, hematopoiesis 
is a strictly regulated process that consists of a series of cell 
lineage commitments, encompassing sequential steps of 
differentiation, including transition of hematopoietic stem 
cells (HSCs) to lymphoid and myeloid precursors and sub-
sequently to mature immune cells, necessary to maintain 
the physiological levels of circulating leukocytes [1]. In 
stress/pathological conditions (e.g. infection and cancer), 
signals derived from the HSCs niche modify the magnitude 
and composition of the hematopoietic output, a feature of 
immune regulation defined as ‘‘emergency’’ hematopoiesis, 
to guarantee proper supply of both lymphoid and myeloid 
cells to increased demand [2]. In particular, in cancer al-
tered myelopoiesis generates lineage-restricted hemato-
poietic progenitors, supporting the expansion of mature 
and immature myeloid cells endowed with tumor-
promoting activities [3]. Within this scenario, tumor-
associated macrophages (TAMs) and myeloid-derived sup-
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αKG – α-ketoglutarate,  
AMPK – adenosine monophosphate kinase, 
BC – breast cancer,  
BM – bone marrow,  
DC – dendritic cell,  
G-CSF – granulocyte colony-stimulating factor, 
HSC – hematopoietic stem cell, 
M-CSF – macrophage colony-stimulating 
factor,  
MDSC – myeloid-derived suppressor cell, 
NAMPT – nicotinamide 
phosphoribosyltransferase, 
pCR – pathologic complete response, 
TAM – tumor-associated macrophage, 
Treg – regulatory T cell.  
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pressor cells (MDSCs) [4] are the main myeloid populations 
rising during tumor development and represent the final 
commitment of the protumoral reprogramming of the my-
eloid lineage. Moreover, Tie-2-expressing monocytes and 
tumor-associated neutrophils (TANs) infiltrate tumors, 
promoting angiogenesis and immunosuppression [5, 6]. 
“Emergency” myelopoiesis emerges in response to 
danger signals and is aimed at elimination of microbial 
threats, tissue repair and recovery of homeostatic condi-
tions. Danger signals are sensed by myeloid cells through 
pattern recognition receptors (PRRs), able to detect patho-
gen-associated molecular patterns (PAMPs), conserved 
among entire classes of pathogens [7], as well as endoge-
nous damage-associated molecular patterns (DAMPs), 
which are produced upon cellular stress and damage [8]. 
These events promote the production of cytokines and 
growth factors, which act through specific transcriptional 
programs that drive differentiation of myeloid cells.  
Among these, interleukin-17A (IL-17A) promotes both 
granulocyte colony-stimulating factor (G-CSF)- and stem-
cell-factor-mediated neutrophilia [9] and supports G-CSF-
driven ‘‘emergency’’ myelopoiesis[10]. IL-1 and IL-6 repre-
sent additional players in emergency myelopoiesis. In par-
ticular, IL-1 has been found to increase the proliferation 
and differentiation rate of HSCs [11] through induction of 
PU.1 and the consequent upregulation of both the macro-
phage colony-stimulating factor (M-CSF;Csf1r) and the 
granulocyte macrophage colony-stimulating factor (GM-
CSF;Csf2ra) receptors. Interestingly, while chemotherapy-
induced inflammation is a mechanism that reinforces aber-
rant myelopoiesis through the generation and expansion of 
MDSCs, IL-6 was confirmed to activate emergency myelo-
poiesis after myeloablation consequent to either cytotoxic 
treatment [12] or irradiation [13, 14]. Thus, the interplay 
between chemotherapy and inflammatory mediators criti-
cally controls the pathological expansion of tumor-
promoting myeloid cells. Myelopoiesis is also critically af-
fected by metabolism. In particular, cancer cells display 
increased glucose uptake and fermentation of glucose to 
lactate, even in the presence of completely functioning 
mitochondria. A major side effect of this event is immuno-
suppression, characterized by limited immunogenicity of 
cancer cells and restriction of the therapeutic efficacy of 
anticancer immunotherapy[15]. Correcting the pathologi-
cal expansion of tumor-promoting myeloid cells during 
tumor growth appears therefore to be a promising strategy 
to improve anticancer responses and to generate more 
effective therapies. 
 
ORIGIN OF MYELOID SUPPRESSOR CELLS 
In acute inflammation, notably during acute infections, 
myeloid progenitors expand and differentiate into activat-
ed pro-inflammatory monocytes, which eventually migrate 
into tissues where they mature to macrophages and den-
dritic cells (DCs) [16, 17]. Expansion of suppressor myeloid 
cells is peculiar to chronic inflammatory states (e.g. cancer, 
chronic infection and autoimmune disease), impairing the 
differentiation of myeloid progenitors into mature immune 
cells and leading to the expansion and accumulation sup-
pressor myeloid cells, including MDSCs and TAMs [4]. Their 
expansion is an hallmark of cancer-immunosuppression 
and a major obstacle to anticancer treatments, since these 
populations exert a primary role in the organization of the 
immunosuppressive microenvironments [18, 19]. The de-
tailed description of the mechanisms used by TAMs and 
MDCSs to promote tumor growth has been widely de-
scribed in other works [3, 20] and goes beyond the scope 
of this review. Beyond being highly heterogeneous, TAMs 
and MDSCs are also highly plastic [21] and the surrounding 
microenvironment influences their functions to promote 
tumor development and to suppress immune responses 
through multiple mechanisms, including: depletion of me-
tabolites critical for T cell functions, expression of immune 
checkpoint inhibitors, secretion of immunosuppressive 
molecules, production of reactive oxygen and nitrogen 
species, regulation of lymphocyte homing, expansion of 
regulatory T (Treg) cells [18]. In particular, TAMs are con-
sidered crucial orchestrators of cancer-related inflamma-
tion because they promote angiogenesis, immunosuppres-
sion, tissue remodeling and metastasis [20, 22]. The pro-
tumoral phenotype of TAMs is dictated by microenviron-
mental signals, which exploit the functional plasticity of 
macrophages, defined as the capacity to acquire a variety 
of functional states in response to different environmental 
stimuli. Indeed, in vitro macrophages activated by lipopoly-
saccharide (LPS) in the presence or absence of interferon-γ 
(IFNγ) (classically or M1/[LPS ± IFNγ]-activated) and those 
stimulated by IL-4 (alternatively or M2/[IL-4 ± IL-13]-
activated) represent the extreme ends of a continuum of 
polarization states. Polarized macrophages differ in terms 
of receptors expression, cytokines/chemokines production, 
and effector functions. Although it is an oversimplification, 
the TAM's phenotype mostly resembles that of M2-like 
polarized macrophages. The phenotype of TAMs is strongly 
influenced by microphysiological conditions present in the 
surrounding microenvironment (e.g. hypoxia, interstitial 
hyperpression, low glucose levels) and molecularly and 
functionally distinct TAM subsets can simultaneously exist 
[23].  
Along with TAMs, MDSCs are characterized by the ca-
pacity to suppress T cell functions and support tumor pro-
gression[3, 17]. These cells comprise at least two subsets: 
monocytic MDSCs (identified as CD11b+Ly6G−Ly6Chi cells in 
mouse and CD11b+CD14+HLA‐DRlow/−CD15− cells in human) 
and granulocytic MDSCs (PMN-MDSCs, identified as 
CD11b+Ly6G+Ly6Clo cells in mouse and CD11b+CD14−CD15+ 
or CD11b+CD14−CD66+ cells in human) [24]. Despite the 
extensive literature on MDSCs, a consensus regarding the 
cellular definition of MDSC subsets has not yet been 
reached, as no specific markers exist to identify them une-
quivocally [24]. Nevertheless, due to the development of 
more sophisticated biochemical and gene expression pro-
filing techniques, these cells are emerging as a pathologi-
cally activated population of immature myeloid cells. 
Therefore, on the basis of a panel of molecular, biochemi-
cal, and functional markers, an algorithmic approach to 
define cells as MDSCs has been proposed [17].  
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Globally, accumulation of myeloid progenitors and 
their differentiation to TAMs and MDSCs is the result of a 
process driven by cancer-related inflammation [25], involv-
ing: altered myelopoiesis; mobilization of myeloid precur-
sors from the BM to periphery; recruitment of MDSCs and 
TAMs precursors into both secondary lymphoid organs 
and/or tumor tissues; functional diversion of myeloid cells 
in response to microenvironmental signals. This multistep 
process drives the reprogramming of myeloid cells towards 
a tumor-promoting phenotype and remotely controls the 
composition of the tumor-microenvironment. In support of 
this scenario, we recently showed that myeloid-specific 
expression of the retinoic-acid related orphan receptor 
(RORC1/RORγ) marks advanced cancer-inflammation [26] 
and expansion of circulating RORC1+ myeloid cells is asso-
ciated with increased number of both immature suppres-
sive cells (MDSCs) and TAMs [26]. We also reported that 
the M-CSF elevates the myeloid cell levels of nicotinamide 
phosphoribosyltransferase (NAMPT), the rate-limiting en-
zyme in the NAD salvage pathway, which acts as negative 
regulator of the CXCR4 retention axis of hematopoietic 
cells in the BM [27], hence promoting mobilization of mye-
loid cells to periphery. In agreement, NAMPT inhibition 
prevented MDSCs mobilization, reactivated specific anti-
tumor immunity and enhanced the antitumor activity of 
immune checkpoint inhibitors [27].  
Additional evidences indicate that accumulation of 
TAMs and MDSCs in tumor tissues, as well as in metastasis, 
is guided by specific chemotactic pathways (eg. CCL2, M-
CSF, CXCL2) [3, 28], suggesting possible therapeutic strate-
gies to limit their recruitment and contribution to tumor 
growth. Lastly, microenvironmental signals and conditions, 
such as immunosuppressive cytokines (eg, IL-10, TGFβ) and 
hypoxia [29-31], dictate the final protumoral commitment 
of myeloid cells. Hence, this multistep process of myeloid 
cell reprogramming (Figure 1) may offer different levels of 
potential therapeutic interventions.  
Similarly, activation and differentiation of DCs, the 
most potent antigen-presenting cells (APCs) of the immune 
system, is influenced by tumor growth, as well as by in-
flammatory and metabolic disorders [32]. Tumors alter 
host hematopoiesis and induce large numbers of immature 
DCs with immune suppressive properties. In addition, can-
cer cells produce immune suppressive factors (VEGF, IL-10, 
PGE2) that disable DC differentiation, maturation, migra-
tion, and functions [33]. Interestingly, while the 27 hy-
droxycholesterol (27HC) acts on HSCs via ERα to increase 
their proliferation and mobilization [34], oxysterols, that 
rise through enzymatic and non-enzymatic oxidation of 
cholesterol [35], interact with liver X receptors (LXRs) ex-
erting an anti-inflammatory role on macrophages and DCs 
[36]. In agreement, oxysterols produced by tumor cells 
impair antigen presentation by inhibiting CCR7 expression 
on DCs [37]. Furthermore, DCs’ immunogenicity is ham-
pered by both TAMs and MDSCs, through the production 
of copious amount of indoleamine 2,3 dioxygenase 1 
(IDO1) that converts tryptophan into kynurenines [38]. DCs 
differentiation is also affected by the gut microbiota, which 
may play a determinant role in the response to anticancer 
therapies. In particular, cancer chemotherapy and immu-
notherapy cause damage to intestinal epithelial barrier 
allowing bacteria translocation and/or changes in microbial 
composition, producing an adjuvant effect [39, 40]. Of rel-
evance, Bifidobacterium species are associated with an 
anti-tumor response promoted by an enhanced activation 
of DCs, increased frequency of CD8+ T cells and greater 
response to anti-PD-L1 treatment [41]. Recent studies have 
also highlighted the role of energy metabolic pathways in 
the differentiation and function of myeloid cells [42]. In 
this regard, the deranged metabolic flux of cancer cells, 
characterized by aerobic glycolysis (Warburg effect) [47], 
results in the preferential conversion of pyruvate to lactate, 
which in turn impairs cytolytic T cell functions, and matura-
tion of DCs [43]. 
 
TRANSCRIPTIONAL CONTROL OF MYELOPOIESIS 
The transcriptional basis guiding emergency myelopoiesis 
has only been partially clarified. Whereas C/EBPα appears 
to be a major regulator of ‘‘steady-state’’ granulopoiesis 
[44], C/EBPβ [45] and Signal Transducer and Activator of 
Transcription 3 (STAT3) [46] promote expansion and matu-
ration of neutrophils under emergency conditions. Fur-
thermore, while in acute inflammation the C/EBPα inter-
acts with the p50 NF-κB subunit to stimulate neutrophil 
production [47], C/EBPβ is a critical regulator of altered 
myelopoiesis in cancer bearers, contributing to the accu-
mulation of MDSC and to the creation of an immunosup-
pressive environment [48]. Noteworthy, the BCR–ABL fu-
sion protein activates emergency granulopoiesis by up-
regulating C⁄EBPβ, which in turn might support chronic 
myeloid leukemia [49].  
Terminal macrophage differentiation is instead induced 
by M-CSF through activation of the transcription factors 
PU.1 and IRF8 [50]. We have recently shown that myeloid-
specific expression of RORC1/RORγ marks advanced cancer 
stages [26] and orchestrates emergency myelopoiesis by 
suppressing negative (Socs3 and Bcl3) and promoting posi-
tive (C/EBPβ) regulators of granulopoiesis, as well as the 
key transcriptional mediators of myeloid progenitor com-
mitment and differentiation to the monocytic/macrophage 
lineage (IRF8 and PU.1). Interestingly, IRF8 also functions 
as a "master" negative regulator of MDSC generation[51]. 
This plastic commitment of myeloid progenitors is further 
highlighted by the observation that, via HIF-1α activation, 
hypoxia redirects the differentiation of MDSCs toward tu-
mor-associated macrophages, hence providing a mechanis-
tic link between different myeloid suppressive cells in the 
tumor microenvironment [31].  
Epigenetic modifications are also important regulators 
of myeloid cell functions. Recent studies demonstrate that 
chromatin-modifying enzymes could sense the macro-
phage’s metabolic status (i.e. availability of acetyl-
coenzyme A, S-adenosylmethionine, α-ketoglutarate (αKG), 
nicotinamide adenine dinucleotide and polyamines) to 
promote their transcriptional reprogramming and pheno-
typic changes [52]. Of relevance, Liu PS et al. recently 
demonstrated that αKG produced by glutaminolysis is an 
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anti-inflammatory metabolite that augments M2 activation 
and controls metabolic reprogramming of M2 macrophag-
es through the Jumonji domain containing-3 (Jmjd3)-
dependent regulations [53]. Furthermore, epigenetic si-
lencing of the retinoblastoma gene operated by histone 
deacetylase 2 (HDAC-2) drives the transdifferentiation of 
M-MDSCs into PMN-MDSCs in cancer [54]. 
 
HOST METABOLISM AND MYELOPOIESIS 
HSCs are mainly found in secured niches in the BM and are 
programmed for enforced quiescence. This “dormancy 
state” allows adult HSCs to be ready for quick and massive 
production of blood cells under emergency conditions, 
while limiting their proliferation to routinely production of 
blood cells. Therefore, under normal conditions, adult HSCs 
divide rarely to maintain low production of committed 
progenitor cells and refill the HSCs pool. However, they can 
rapidly and transiently proliferate in response to many 
inflammatory signals [55] such as acute infection, becom-
ing rapidly activated for terminal differentiation and func-
tional maturation, to exert their specialized immune func-
tions against pathogens. Understanding how hematopoie-
sis is altered upon environmental stress is currently a ma-
jor focus of research [56], addressed in preclinical models 
challenged with hematopoietic stresses such as infection or 
chronic inflammation. This metabolic influence has been 
extensively studied also under conditions of altered host 
metabolism, such as in the obese patients [57, 58]. Indeed, 
obesity-induced chronic inflammation is a key component 
in the pathogenesis of both insulin resistance and metabol-
ic syndrome and is characterized by continuous production 
of proinflammatory cytokines that can lead to significant 
alteration in HSCs function and output [15, 59]. In differ-
ence to acute inflammatory stress, inducing a response 
that is quickly suppressed upon restoration of tissue ho-
meostasis, failure to efficiently resolve inflammatory in-
sults can have serious consequences for tissue mainte-
nance and function. Indeed, in the context of chronic in-
flammation due to metabolic diseases such as obesity and 
type 2 diabetes, the inflammatory stress fails to resolve, 
leading to a persistent inflammatory state [15, 59].   
Obesity, in fact, leads to a chronic inflammatory pheno-
type favoring the infiltration of activated immune cells into 
the adipose tissue and can be considered as a chronic 
pathological state associated with BM stresses [60]. In par-
FIGURE 1: Myeloid cell reprogramming in cancer: a dynamic multistep process. Cancer-related inflammation promotes emergency myel-
opoiesis through production of colony stimulating factors, such as macrophage-colony stimulating factor (M-CSF), granulocyte-colony 
stimulating factor (G-CSF), granulocyte-macrophage- colony stimulating factor (GM-CSF). The transcription factor RORC1 is a key mediator 
of this myelopoietic response in emergency. Deactivation of anchoring signals, such as the retention axis CXCR4/CXCL12 promotes mobili-
zation of myeloid cells to periphery and allows their accumulation to lymphoid organs, as well tumor tissues. Recruitment of myeloid cells 
into the tumor microenvironment expose these cells to additional signals and conditions that further boost their functional reprogram-
ming towards a tumor-promoting phenotype. CSFs - Colony-stimulating factors, TDFs - tumor-derived factors, TEM - TIE2-expressing mon-
ocytes, PMN - polymorphonuclear cells, Mo – monocytes, MDSCs - myeloid-derived suppressor cells. 
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allel, diabetes adversely impacts the mobilization capacity 
of HSCs by altering chemokine expression in the BM niche 
[61]. 
Of note, impaired blood system function is a common 
feature of these conditions, characterized by cytopenia in 
one or more lineages, anemia, thrombocytosis, suppres-
sion of lymphopoiesis, overproduction of myeloid cell pop-
ulations that mediate further damage, or suppression of 
BM function [56, 62]. These data support the hypothesis 
that the enforced quiescence status prevents HSCs deple-
tion during disease-induced chronic inflammation and sug-
gest that the multipotent progenitor (MPP) compartment, 
which is responsible for everyday blood maintenance, may 
compensate ongoing needs, minimizing continued HSCs 
proliferation. In this perspective, it might also be consid-
ered that HSCs exhibit a finite replicative potential and 
chronic inflammation, or serial inflammatory episodes that 
induce HSCs proliferation, may create a maladaptive con-
text, leading to HSCs decline and BM niche dysfunction. 
These findings have indeed raised new questions on the 
different impacts of inflammation on HSCs fate and func-
tion. The presence of a chronic inflammatory status associ-
ated with insulin resistance has also been linked with a 
higher risk of developing several types of cancer [63] by a 
number of epidemiological studies.  
This association is biologically plausible as hyperinsu-
linemia induces proliferative tissue abnormalities due to 
the strong anabolic effect of insulin, resulting in the en-
hancement of DNA synthesis and cell proliferation. Fur-
thermore, in patients with breast cancer (BC), higher circu-
lating insulin levels have been found to be associated with 
an adverse outcome [64]. Recent evidence also indicates 
that the presence of insulin resistance is associated with a 
significantly worse prognosis in patients with advanced BC 
treated with chemotherapy [65]. Obesity itself has been 
hypothesized to impact response to chemotherapy, not 
only through metabolic perturbations such as the underly-
ing insulin resistance status, hyperglycemia, adpokine pro-
duction, and insulin-like growth factor (IGF)-1 system, but 
also affecting drug delivery, pharmacokinetics and 
transport. However, epidemiological studies in patients 
treated with chemotherapy have produced inconsistent 
results, with some showing an adverse effect and others a 
protective effect [66]. 
In cancer patients hematopoiesis is characterized by an 
increase in myeloid differentiation, which is believed to 
give an important contribution to the establishment of an 
immunosuppressive environment [67]. This is mainly due 
to the accumulation of MDSCs, that suppress adaptive im-
munity favoring cancer cell proliferation, tumor growth 
and survival, angiogenesis and metastasis. Under this hy-
pothesis, the relationship between insulin resistance, obe-
sity, metabolic impairment, with the underlying chronic 
inflammatory status and cancer needs to be extensively 
evaluated and approached in a multidisciplinary fashion. 
Indeed, the recent evidence [68] that patients with a high-
er Body Mass Index (i.e. overweight or obese) have an im-
proved outcome if treated with immunotherapy for ad-
vanced tumors [69], indicates that the immune system, its 
targeting by cancer immunotherapy and patient metabolic 
status are closely connected. It is therefore critical to un-
derstand the potential effects of metabolic impairment on 
cancer related immunity, to improve treatment outcome 
with immuno-targeting. 
 
CELL METABOLISM AND MYELOPOIESIS 
The relationship between metabolic alterations and the 
tumor-promoting functions of myeloid cells is further 
emerging as a crucial aspect of TAMs and MDSCs skewing 
toward pro-tumoral activities and their metabolic re-
education appears as a new strategy to boost antitumor 
effector functions [15]. Within this scenario, the use of 
pharmacological agents to manipulate cell metabolism is 
an important step forward in the development of clinically 
relevant strategies. As an example, metabolites and meta-
bolic regulators such as lactic acid, HIF1, c-Myc, adenosine 
monophosphate kinase (AMPK), and mTOR, which control 
metabolic reprogramming of immune cells and tumor cells, 
are being tested for targeting. Drugs targeting the lactate 
transporters MCT1 and MCT2 [70] and AMPK (e.g., met-
formin) are being evaluated for anti-tumor effects in pre-
clinical models and in clinical trials [71].  
Interestingly, besides affecting tumor cells, metformin 
has a direct effect on infiltrating immune cells: increasing 
CD8+ T cell recruitment, protecting them from apoptosis 
and exhaustion, increasing CD8+ memory T cells and 
providing a better response to anti-cancer vaccines [59]. 
Moreover, accumulating evidences indicate that AMPK, 
which is a central regulator of fatty acid, cholesterol, and 
glucose homeostasis, also skews macrophages polarization 
towards the M2 phenotype. More recently it was shown 
that in MDSCs, PPARγ plays a critical role in neutral lipid 
metabolism signaling controlled by lysosomal acid lipase 
(LAL) and that enhanced PPARγ activity impairs MDSCs-
mediated proliferation and spreading of cancer cells [72]. 
Of note, both mouse and human tumor-infiltrating MDSCs, 
which accumulate during cancer progression, show a pref-
erential increase of fatty acid uptake and fatty acid oxida-
tion over glycolysis [73]. This metabolic profile is shared by 
M- and PMN-MDSCs subsets and dictates their immuno-
suppressive behavior inside the tumor [73]. Further, up-
regulation of fatty-acid synthase (FASN) by M-CSF in tumor 
infiltrating myeloid cells was required for PPARβ/δ-
dependent expression of immunosuppressive and pro-
angiogenic genes (e.g. IL-10, Arg1 and VEGF) and conse-
quent promotion of tumor progression [74], in a model of 
Lewis lung cancer. 
In this perspective, the antitumor effect of metformin 
was recently evaluated in two prospective, randomized 
trials, in non-diabetic women affected by early and ad-
vanced BC. The first one was a window of opportunity, 
double-blind, randomized study in early BC patients, can-
didate to surgery: in this setting, the administration of met-
formin single agent for four weeks before surgery, did not 
impact tumor proliferation, compared to baseline levels, in 
the overall patient population. However, a significant ef-
fect was seen in insulin-resistant patients [75]. In the met-
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astatic setting, the addition of metformin to first-line 
chemotherapy as compared to chemotherapy alone, did 
not improve progression free survival or overall survival. Of 
note, patients receiving the combination of metformin and 
chemotherapy experienced significantly lower severe neu-
tropenia as compared to chemotherapy alone, suggesting a 
protective effect on BM toxicity [65]. A large adjuvant trial 
on non-diabetic women with early BC comparing metfor-
min with matching placebo in terms of disease-free surviv-
al (DFS) is currently ongoing.  
 
CHEMOTHERAPY EFFECTS ON MYELOPOIESIS AND 
IMPLICATION FOR IMMUNOTHERAPY 
Malignant transformation and progression cannot occur 
without the aid of host-derived factors. The interplay 
among tumor cells, stroma and immune system cells con-
tributes to the shaping of tumor microenvironment where 
reprogrammed non-cancer cells sustain angiogenesis, cell 
growth, diversion and skewing of adaptive response. As 
previously discussed, the myeloid compartment plays a key 
role in this tumor reconditioning, which results in the gen-
eration of myeloid cells with special immunosuppressive 
properties. Of note, atypical myelopoiesis has also been 
described in hematologic malignancies including multiple 
myeloma, leukemias and lymphomas. In this perspective, 
acute and chronic myeloid leukemia can be considered the 
most extreme examples of deregulated myelopoiesis [76]. 
Chemotherapy represents an important component of 
the therapeutic armamentarium against cancer. More re-
cently, restoring immune response with immune check-
point inhibitors has emerged as an efficient treatment for 
several cancer types. Even though apparently counterpro-
ductive, the combination of these two strategies resulted 
in clinically meaningful results [77-79]. Indeed, chemother-
apy has been historically viewed as immunosuppressive 
mainly because of its lymphodepleting effect. However, 
chemotherapy effects on the immune system are extreme-
ly complex. Most preclinical studies support chemothera-
py-induced inflammation as a mechanism to reinforce ab-
errant myelopoiesis, through the generation and expansion 
of MDSCs. This effect is suggested as a counter-regulatory 
adaptation to prevent unnecessary damage from a chemi-
cal insult [80]. Enhancement of MDSCs suppressive activity 
is described with doxorubicin and with high-dose cyclo-
phosphamide, among others [81]. In contrast, other pre-
clinical data have shown that a number of cytotoxic agents, 
such as gemcitabine, docetaxel and 5-fluorouracil, can in-
duce MDSCs apoptosis [82-84]. Cyclophosphamide can be 
considered the paradigm of the complexity of the interplay 
between chemotherapy and the immune system, since 
both immuno-stimulating effects as well as induction of 
immunosuppressive cells have been described with this 
cytotoxic agent [85]. Indeed, MDSCs accumulation was 
reported by several authors [86, 87]. However, when ad-
ministered at low dose, cyclophosphamide causes Treg cell 
depletion, augmenting antitumor response and increasing 
expression of DC maturation markers [88, 89]. Data from 
clinical studies prospectively evaluating the effects of 
chemotherapy on MDSCs are scanty, and the results 
somewhat conflicting. Diaz et al. [90] evaluated 17 stage II-
III BC patients treated with adjuvant dose-dense doxorubi-
cin-cyclophosphamide (AC) followed by dose dense 
paclitaxel [91]. A significant increase in MDSCs was de-
scribed after dose-dense AC. More recently, in 24 BC pa-
tients undergoing neoadjuvant sequential chemotherapy, a 
significant increase in granulocytic-MDSC was reported 
after AC therapy, with subsequent decrease to near base-
line levels during paclitaxel treatment [90]. PMN-MDSCs 
levels at the last draw were numerically lower in patients 
with pathologic complete responses (pCRs) versus patients 
with no pCR. However, these data are far from being con-
clusive, considering the limited sample size, the inclusion 
of heterogeneous patient population with respect to hor-
mone receptor and HER2 expression, as well as the use of 
G-CSF. Indeed, G-CSF is one of the key drivers of aberrant 
expansion of myeloid cells, and the common use of exoge-
nous G-CSF in cancer patients undergoing chemotherapy 
might play a role in the immunosuppressive status induced 
by the tumor. The largest study so far included 56 patients 
with locally advanced BC undergoing neoadjuvant therapy 
with sequential AC followed by docetaxel+/- capecitabine 
[92]. In contrast to the findings of the other two trials, 
monocytic and granulocytic MDSCs were significantly re-
duced after both four and eight courses of chemotherapy, 
irrespective of response. Interestingly, circulatory levels of 
Treg were significantly associated with pathologic response.  
In patients with non-small cell lung cancer treated with 
first-line platinum-based chemotherapy, higher M-MDSCs 
significantly correlated with worse outcome. However, 
dynamic changes of MDSCs during chemotherapy were not 
evaluated [93]. In 23 patients with advanced colorectal 
cancer, decreased levels of MDSCs were observed after 
therapy with 5-fluorouracil combined with oxaliplatin 
(FOLFOX), while persistent increase of MDSCs was reported 
after 5-fluorouracil combined with Irinotecan (FOLFIRI) [94]. 
As a whole, these data suggest that chemotherapy can 
impact on the tumor microenvironment by promoting anti-
tumor immune response, or by inducing MDSCs that coun-
ter-regulate immune response. 
Immunotherapy is now established as a ground-
breaking strategy in several tumors; however, a significant 
proportion of patients does not respond or even experi-
ence hyperprogression. Taking into account the costs, as 
well as the potential side effects of these treatments, ade-
quate patient selection is highly needed. Tissue biomarkers 
are promising, but not suitable for dynamic evaluation. In 
this context, circulating immune-related biomarkers are 
particularly attractive. Peripheral blood mononuclear cells 
phenotyping is considered a dynamic marker to evaluate 
pre-existing immunity that could affect outcome and sensi-
tivity to treatments. MDSCs levels have been associated 
with prognosis in ipilimumab-treated patients. In particular, 
on-treatment high levels of CD14+/IL4Rα+ MDSCs were 
negative independent factors of reduced overall survival in 
a cohort of melanoma patients treated with ipilimumab 
[95]. 
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Prospective MDSCs and TAMs evaluation in trials of 
chemo-immunotherapy could elucidate the mechanisms 
underlying different tumor behaviors upon treatment ex-
posure. Moreover, identifying the drivers of treatment 
resistance can be helpful to select potential targets to re-
store antitumor immune response. 
 
CONCLUSIONS 
Solid tumors are composed by cancer cells, stroma and a 
variety of infiltrating immune cells, which establish recip-
rocal relationships that dictate the clinical outcome. De-
spite this evidence, the mechanisms leading to accumula-
tion of tumor-promoting myeloid cells in the tumor micro-
environment are far from being understood, though might 
likely be the sum of sequential alterations targeting: differ-
entiation of myeloid progenitors and their mobilization to 
periphery; their recruitment to both secondary lymphoid 
organs and tumor tissues; their functional diversion in re-
sponse to microenvironmental signals and conditions. Ef-
forts are being made to characterize the immunostimulato-
ry properties of chemotherapeutic agents and how they 
can be best combined with immune checkpoint inhibitors 
and new evidence indicates that chemotherapeutics (e.g. 
paclitaxel acting as TLR4 agonist) [96] can restore the anti-
cancer activity of TAMs and improve the clinical efficacy of 
immune checkpoint inhibitors. In this perspective, while 
the tumor microenvironment has been considered as a 
suitable target for therapeutic interventions, new studies 
should carefully evaluate the impact of therapies on the 
quality and extent of the hematopoietic response, aiming 
to differentially target multiple levels of the tumor-
promoting reprogramming of myeloid cells. The analysis of 
the effects and mechanisms elicited by different chemo-
therapeutics, dose and timing of administration, as well as 
their interplay with metabolic traits, seems therefore cru-
cial to establish the drivers of myelopoietic alterations as-
sociated with tumor progression and for a correct stratifi-
cation of patients, in order to achieve a rational combina-
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